Compare LPG & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LPG | ADMA |
|---|---|---|
| Founded | 2013 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.0B |
| IPO Year | 2014 | 2012 |
| Metric | LPG | ADMA |
|---|---|---|
| Price | $54.97 | $10.59 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $54.60 | $17.00 |
| AVG Volume (30 Days) | 541.7K | ★ 3.1M |
| Earning Date | 11-05-2026 | 11-04-2026 |
| Dividend Yield | ★ 5.09% | N/A |
| EPS Growth | ★ 112.15 | N/A |
| EPS | ★ 3.24 | 0.35 |
| Revenue | ★ $481,511,242.00 | $42,219,783.00 |
| Revenue This Year | $32.64 | $4.93 |
| Revenue Next Year | N/A | $17.59 |
| P/E Ratio | ★ $17.90 | $29.54 |
| Revenue Growth | 36.27 | ★ 43.85 |
| 52 Week Low | $23.76 | $7.21 |
| 52 Week High | $59.97 | $20.46 |
| Indicator | LPG | ADMA |
|---|---|---|
| Relative Strength Index (RSI) | 48.27 | 65.11 |
| Support Level | $52.09 | $9.23 |
| Resistance Level | $59.97 | $11.42 |
| Average True Range (ATR) | 2.00 | 0.39 |
| MACD | -0.23 | 0.05 |
| Stochastic Oscillator | 29.90 | 98.54 |
Dorian LPG Ltd is an international liquefied petroleum gas shipping company focused on owning and operating gas carriers, or VLGCs. The company currently owns and operates around 22 modern VLGCs, including nineteen new fuel-efficient 84,000 cbm ECO-design VLGCs. Dorian LPG has offices in Connecticut, USA, London, United Kingdom, and Athens, Greece. IT operates in one reportable segment, the international transportation of LPG.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.